| Literature DB >> 35052765 |
Linlin Wang1,2,3,4, Ting Jiao2,3, Qiangqing Yu2,3, Jialiang Wang2,3, Luyao Wang2,3, Gang Wang2,3,4, Hao Zhang2,3,4,5,6, Jianxin Zhao2,3,4, Wei Chen2,3,5.
Abstract
The occurrence of non-alcoholic fatty liver disease (NAFLD) is closely related to intestinal microbiota disturbance, and probiotics has become a new strategy to assist in alleviating NAFLD. In order to investigate the effect of Bifidobacterium on NAFLD and the possible pathway, a NAFLD model was established by using a high-fat diet (HFD) for 18 weeks. Fourteen strains of Bifidobacterium were selected (seven Bifidobacterium adolescentis and seven Bifidobacterium bifidum) for intervention. The effects of different bifidobacteria on NAFLD were evaluated from liver cell injury, liver fat deposition, liver inflammatory state and liver histopathology, and were taken as entry points to explore the mitigation approaches of bifidobacteria through energy intake, lipid metabolism, glucose metabolism and intestinal permeability. The results showed that Bifidobacterium exerts species-specific effects on NAFLD. B. bifidum exerted these effects mainly through regulating the intestinal microbiota, increasing the relative abundance of Faecalibaculum and Lactobacillus, decreasing the relative abundance of Tyzzerella, Escherichia-Shigella, Intestinimonas, Osillibacter and Ruminiclostridium, and further increasing the contents of propionic acid and butyric acid, regulating lipid metabolism and intestinal permeability, and ultimately inhibiting liver inflammation and fat accumulation to alleviate NAFLD. B. adolescentis exerted its effects mainly through changing the intestinal microbiota, increasing the content of propionic acid, regulating lipid metabolism and ultimately inhibiting liver inflammation to alleviate NAFLD.Entities:
Keywords: Bifidobacterium adolescentis; Bifidobacterium bifidum; gut microbiota; non-alcoholic fatty liver disease; short chain fatty acids
Year: 2021 PMID: 35052765 PMCID: PMC8772902 DOI: 10.3390/biomedicines10010084
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1The effect of Bifidobacterium on liver injury in NAFLD mice. (a) ALT in serum; (b) AST in serum; (c) CHE in serum; (d) TG in liver; (e) TNF-α in liver; (f) IL-1β in liver; (g) IL-6 in liver; (h) Liver histopathology score, (i) Principal Component Analysis of each index of liver injury. (j) Principal component analysis of each index. Mean values with different letters (a–e) over the bars are significantly different (p < 0.05) according to Duncan’s multiple range test.
Figure 2Effects of Bifidobacterium on energy intake and lipid metabolism in NAFLD mice. (a) energy intake; (b) TC in serum; (c) HDL-C in serum; (d) LDL-C in liver; (e) TG in serum; (f) FFA in serum; (g) body weight gain; (h) epididymal fat index. Mean values with different letters (a–d) over the bars are significantly different (p < 0.05) according to Duncan’s multiple range test.
Figure 3Effect of Bifidobacterium on blood glucose metabolism in NAFLD mice. (a) fasting glucose; (b) insulin; (c) HOMA-IR; (d) postprandial blood glucose; (e) AUC of OGTT; (f) curve of OGTT. Mean values with different letters (a–e) over the bars are significantly different (p < 0.05) according to Duncan’s multiple range test.
Figure 4Effect of Bifidobacterium on intestinal permeability of NAFLD mice. (a) the concentration of serum LPS; (b) the ileal histopathology in NAFLD mice treated with different bifidobacteria; (c) the colon histopathology in NAFLD mice treated with different bifidobacterial. Scale bar = 100 μm. Mean values with different letters (a–d) over the bars are significantly different (p < 0.05) according to Duncan’s multiple range test.
Figure 5Effects of Bifidobacterium on SCFAs in NAFLD mice. (a) acetic acid; (b) propionic acid; (c) isobutyric acid; (d) butyric acid; (e) the correlation analysis of SCFAs and hepatic damage; (f) the correlation analysis of SCFAs and alleviation pathways. Mean values with different letters (a–d) over the bars are significantly different (p < 0.05) according to Duncan’s multiple range test. Cell injury indexes: serum ALT, serum AST and serum CHE; hepatic lipid accumulation index: hepatic TG. Liver inflammation indexes: hepatic TNF-α, IL-1β and IL-6. Liver lipid metabolism indexes: HDL-C, LDL-C, serum TC, serum TG, FFA. Epididymal fat index and body weight gain. Sugar metabolism indexes: AUC, HOMA-IR, FBG, PB.; Intestinal permeability index: serum LPS.
Figure 6Effect of Bifidobacterium on intestinal microbiota of NAFLD mice. (a) the LEfSe analysis of gut microbiota after intervention with bifidobacteria in NAFLD mice; (b) Bifidobacterium; (c) Faecalibaculum; (d) Lactobacillus; (e) Blautia; (f) Dubosiella; (g) Escherichia-Shigella; (h) Ileibacterium; (i) Intestinimonas; (j) Oscillibacter; (k) Ruminiclostridium; (l) Ruminiclostridium 9; (m) Tyzzerella. Mean values with different letters (a–e) over the bars are significantly different (p < 0.05) according to Duncan’s multiple range test.
Figure 7Correlation analysis between intestinal microbiota and liver injury.
Figure 8Correlation analysis of intestinal microbiota and other influencing factors.
Figure 9Correlation analysis between intestinal microbiota and SCFAs.